South Korea’s biopharmaceutical companies have had a mixed licensing record this year, with some striking major license-out deals and others losing their contracts over reporting issues related to clinical trials, reports The Korea Herald.

While a slew of early-stage drugs are being licensed out, the biopharma unit of Korea’s SK Group is drawing closer to launching a new sleep disorder drug it has developed to the US market.